Solagran and its manufacturing partner in St Petersburg have received a steady stream of enquiries regarding the availability of Ropren for patients with cirrhosis and other serious liver diseases living in the UK, Western Europe, Scandinavia, North America and Asia. There have also been many enquiries from doctors in the former Soviet Republics (CIS countries).
In response to these requests, Solagran's manufacturing partner has taken the decision to put in place the necessary administrative procedures to enable them to provide Ropren to patients outside Russia, consistent with the specific "compassionate use" and "personal supply" provisions that exist within the regulatory frameworks of each country.
Solagran has agreed to a price in the range 3,500 to 6,000 US Dollars per three month course, after independent confirmation that such a price would compare favourably with that of other therapies currently used to treat serious liver diseases.
Got to be around $2000 at least for supply in Russia doesn't it? Guess we will know sooooooooooon.
SLA Price at posting:
0.0¢ Sentiment: ST Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)